That is a 3.2% increase from the year prior, and a 4.4% increase on a constant currency basis. Additionally, net earnings for the first quarter reached $172.4 million.
Zimmer Biomet saw a 3.4% increase in its total global knee sales in the first quarter, along with a 0.3% decrease in total hip sales.
In the first quarter, the company earned FDA clearance for its Rosa shoulder system and its femoral hip stem and announced partnerships with three top pickleball organizations in the U.S.
The company is now projecting a 4.5% to 5.5% increase in total revenue in 2024.
